Rocket Pharmaceuticals (NASDAQ: RCKT) — Perfil da empresa, notícias e dados financeiros
Rocket Pharmaceuticals is a biotechnology company developing gene therapies for rare pediatric diseases, aiming for transformative treatments.
Rocket Pharmaceuticals
Rocket Pharmaceuticals (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company's pipeline includes projects aimed at addressing genetic disorders through cutting-edge treatments that target the underlying causes of these conditions. With a commitment to innovation and improving patient outcomes, Rocket Pharmaceuticals is dedicated to advancing its gene therapy projects from preclinical stages through clinical trials, with the goal of bringing new, transformative treatments to market. The company operates a patient-centric approach, collaborating with researchers and healthcare professionals to ensure its therapies meet the unmet needs of those affected by rare genetic diseases.
Resumo
Operações
Produtos e/ou serviços de Rocket Pharmaceuticals
- Gene therapy product aimed at treating Fanconi anemia, a rare genetic disorder affecting the bone marrow.
- A lentiviral vector-based therapy for Leukocyte Adhesion Deficiency-I, an immune system disorder.
- Gene therapy targeting Pyruvate Kinase Deficiency, which affects red blood cell metabolism.
- A program focused on treating Danon Disease, a rare inherited condition that affects the heart.
- Gene therapy for Infantile Malignant Osteopetrosis, a disorder causing increased bone density.
- Therapeutic approach for treating Limb-girdle muscular dystrophy, a genetic disorder affecting muscle strength.
equipe executiva do Rocket Pharmaceuticals
- Gaurav D. ShahCEO & Director
- Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer
- Christopher StevensChief Operating Officer
- Joseph ManhedePrincipal Accounting Officer
- Jonathan SchwartzChief Science & Gene Therapy Officer
- Meg E. DodgeSenior Vice President & Head of External Affairs
- Syed Ali-Aamir RizviChief Medical Officer
- Kevin GiordanoDirector of Corporate Communications
Últimas notícias sobre a Rocket Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Rocket Pharmaceuticals, em USD.
- Cap. de mercado
- 283,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -228,5 mi | -223,1 mi | |
| 0 | -273,2 mi | -258,7 mi | |
| 0 | -259,7 mi | -245,6 mi | |
| 0 | -224,3 mi | -221,9 mi |